Development of novel microbiome-driven therapies based on the meta-omics analysis (KAP220130)
The objective of this project is to evaluate and analyze the meta-omics-based gut microbiome of patients suffered from metabolic diseases including type 2 diabetes and inflammatory bowel disease, which the international human microbiome consortium has focused on. Based on the microbiome data, we aim to identify symbiotic microorganisms that either cause or prevent the metabolic diseases and investigate the underlying mechanisms for their actions which are ultimately used to develop therapeutics to manipulate the target diseases.